SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Phaarmasia - Quaterly Results

25 May 2023 Evaluate
An increase of about 80.19% to Rs. 75.03 millions in the topline was observed for the quarter ended March 2023. The topline stood at Rs. 41.64 millions during the similar quarter previous year.The Net Loss for the quarter ended March 2023 is Rs. -0.93 millions as compared to Net Loss of Rs. -1.49 millions of corresponding quarter ended March 2022 Operating profit Margin for the quarter ended March 2023 further decreased to -0.69% as compared to -0.80% of corresponding quarter ended March 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 75.03 41.64 80.19 274.90 172.16 59.68 274.90 172.16 59.68
Other Income 1.41 1.54 -8.44 5.16 4.70 9.79 5.16 4.70 9.79
PBIDT -0.69 -0.80 -13.75 -10.27 -12.65 -18.81 -10.27 -12.65 -18.81
Interest 0.32 0.01 3100.00 0.45 0.04 1025.00 0.45 0.04 1025.00
PBDT -1.01 -0.81 24.69 -10.72 -12.69 -15.52 -10.72 -12.69 -15.52
Depreciation 1.70 0.72 136.11 3.60 2.92 23.29 3.60 2.92 23.29
PBT -2.71 -1.53 77.12 -14.32 -15.61 -8.26 -14.32 -15.61 -8.26
TAX -1.78 -0.04 4350.00 -1.73 -0.15 1053.33 -1.73 -0.15 1053.33
Deferred Tax -1.78 -0.04 4350.00 -1.73 -0.15 1053.33 -1.73 -0.15 1053.33
PAT -0.93 -1.49 -37.58 -12.59 -15.46 -18.56 -12.59 -15.46 -18.56
Equity 68.27 68.27 0.00 68.27 68.27 0.00 68.27 68.27 0.00
PBIDTM(%) -0.92 -1.92 -52.13 -3.74 -7.35 -49.16 -3.74 -7.35 -49.16

Phaarmasia Share Price

113.80 1.80 (1.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×